RESEARCH AREA

Amyotrophic lateral sclerosis (ALS)

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Completed Clinical Trial

2022: Himalaya study (Phase II)

For more information contact Victorine Sikati Foko Recruitment will start in few next weeks

Completed Clinical Trials

2023 BIAL (Phase II)
2021: BN42358 study (Phase IIb)
2014: iSTEP study (Phase III)
2011: CONFIDENT-PD study (Phase II)
2010: AFQ056A2217 study (Phase II)
2010: AFQ056A2208 study (Phase II)

Symptoms & Cause

Symptoms generally develop slowly over years. The progression of symptoms is often a bit different from one person to another due to the diversity of the disease. People with PD may experience:

Tremor, mainly at rest and described as pill-rolling tremor in hands. Other forms of tremor are possible

  • Bradykinesia
  • Limb rigidity
  • Gait and balance problems

The cause remains largely unknown. Although there is no cure, treatment options vary and include medications and surgery. While Parkinson’s itself is not fatal, disease complications can be serious.

Diagnose & Treatment

There is no “one way” to diagnose Parkinson’s disease (PD). However, there are various symptoms and diagnostic tests used in combination. Making an accurate diagnosis of Parkinson’s — particularly in its early stages — is difficult.

There is no standard treatment for Parkinson’s disease (PD). Treatment for each person with Parkinson’s is based on his or her symptoms. Treatments can include medications, physical therapy, surgical options, medical marijuana, clinical trials, lifestyle modifications, like getting more rest and exercise.

There are many medications available to treat Parkinson’s symptoms, although none yet that reverse the effects of the disease. It is common for people with PD to take a variety of these medications — all at different doses and at different times of day — to manage symptoms.

Importance of clinical research

Scientists and doctors are working together to find a treatment or prevention technique. The clinical research will help to attract the attention of the federal and state government as well as the pharmaceutical industry to the growing need and urgency in addressing PD. This is an important first step to better understanding who develops PD and why. We participate in a number of clinical trials aiming to create advancements for the treatment of Multiple Sclerosis, Stroke, Parkinson’s, Alzheimer’s and Glioblastoma Multiforme (GBM). Our participation allows us to offer many treatments long before they become available to a majority of specialists, giving patients an opportunity to choose from a wide range of care that, while experimental in nature, may possibly be more effective. Cutting edge treatments aren’t the only reason we conduct clinical trials, nor are they the only reason patients decide to participate. Our involvement gives us the opportunity to develop better protocols and, most importantly, to help advance the treatments themselves. When it comes to Neurological diseases, large strides have been made in recent years; results that would have been impossible without the participation of Doctors, Nurses and, most of all, patients.

Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS) is a rare neurodegenerative disease affecting both the central and peripheral nervous systems, with an estimated incidence of 1 to 3 cases per 100,000 people per year.

Participate

Amyotrophic Lateral Sclerosis (ALS)

ALS is characterized by progressive weakness, muscle atrophy, and stiffness in the limbs or bulbar muscles, which control speech and swallowing. In some individuals, it may also be accompanied by cognitive changes and alterations in personality.


ALS is a uniformly fatal condition, with most patients surviving an average of 3 to 5 years after diagnosis. The underlying cause and disease mechanisms remain poorly understood.


While current medications such as Riluzole and Edaravone (Radicava) may modestly extend survival, they do not halt disease progression or improve quality of life. Supportive therapies, physiotherapy, occupational therapy, nocturnal ventilation assist, nutritional assistance via feeding tube etc., remain the mainstay of treatment.


Research is ongoing for both symptomatic treatment and disease modifying therapies.


Non-invasive neuro modulation using repetitive transcranial magnetic stimulation (rTMS) has been shown to alleviate ALS symptoms, including weakness and spasticity.


rTMS is however still considered an experimental treatment and is not yet covered by public health plans (RAMQ/OHIP)

Completed Clinical Trial

2022: Himalaya study (Phase II)

Studies Recruiting

Please inquire. As of writing CNO does not have a trial recruiting.

Studies Ongoing

Please inquire. As of writing CNO does not have a trial ongoing.

Completed Studies

2022: Himalaya study (Phase II)